drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR-NK)
drug_description
Genetically engineered natural killer cells expressing a CD19-specific chimeric antigen receptor; designed to bind CD19 on B-ALL cells and trigger NK-mediated cytotoxicity.
nci_thesaurus_concept_id
C170903
nci_thesaurus_definition
A preparation of natural killer (NK) cells engineered to express an inhibitory chimeric antigen receptor (iCAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 iCAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The iCAR is designed to spare normal cells from NK cell actions by including an inhibitory receptor that is activated upon binding to antigens that are present on normal cells only. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Receptors, Chimeric Antigen
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Genetically engineered natural killer cells expressing a CD19-specific chimeric antigen receptor bind CD19 on malignant B cells, redirecting and activating NK effector functions (perforin/granzyme-mediated cytotoxicity and cytokine release) to selectively lyse CD19-positive B-ALL cells, independent of MHC.
drug_name
Anti-CD19 CAR-NK cells
nct_id_drug_ref
NCT06631040